WG3: HIV, Co-infections and Co-morbidities

虽然抗逆转录病毒疗法（ART）已经大大改变了HIV感染的预后， 提高了患者的存活率，受感染的患者继续遭受结核病的显著发病率和死亡率， CVD、恶性肿瘤、慢性肾脏和神经认知疾病。这些问题突出表明，虽然ART 在限制病毒复制方面非常有效，迫切需要解决合并症的决定因素， 这是艾滋病毒研究中的关键问题，也是第3工作组议程的重点。的 该小组的职责是为CFAR确定这一领域的科学优先事项，然后促进 通过促进协同互动和合作研究提案，并推进 初级调查员工作组有23名成员，包括临床和翻译的临界质量 研究人员在上一个资助周期内共同发表了423篇同行评审的出版物。的 WG3的主要目标是促进CWRU及其他研究人员之间的互动和合作 来解开HIV感染的生物共病条件。 第三工作组通过各种活动促进这一科学议程，包括（1）促进合作， 通过赞助研讨会、期刊俱乐部、研究进展会议和有针对性的会议， 讨论艾滋病毒倡议，（2）成立和参加国家研究联盟，以促进和传播 艾滋病毒研究，以及（3）指导和促进初级研究人员的职业生涯。通过这些活动， 将促进以下具体目标： ·在不同学科的研究人员之间建立新的互动关系。关键科学 优先事项是： ·鼓励形成多调查员项目。WG2的成功将由 推进新的合作项目，包括： ·鼓励各工作组之间的交流。 总之，第三工作组的重点是促进ART时代艾滋病毒研究的关键科学优先事项。这 将通过旨在促进CWRU/UH内部合作的有针对性的活动来支持该议程 CFAR，开发CFAR核心的支持资源，特别是临床核心D和乌干达实验室 核心C。第三工作组重视聘用新的调查人员，并在支持和协助调查方面有着出色的记录。 指导科学家试点赠款和催化基金获奖者的工作。

Although antiretroviral therapy (ART) has dramatically altered the prognosis of HIV infection and improved the survival of patients, infected patients continue to suffer significant morbidity and mortality from TB, CVD, malignancies, chronic kidney, and neurocognitive disease. These issues highlight the fact that while ART is very effective at restricting viral replication, there is a pressing need to address the determinants of comorbidities, which are the critical issues in HIV research and the focus of the Working Group 3 agenda. The group has a remit to define scientific priorities in this area for the CFAR and then to facilitate advances in the field by promoting synergistic interactions and collaborative research proposals and advancing the careers of junior investigators. Working Group has 23 members, comprising a critical mass of clinical and translational researchers who have collectively published 423 peer-reviewed publications during the last funding cycle. The primary goal of WG3 is to promote interactions and collaborations between researchers at CWRU and beyond to unravel the biology co-morbid conditions in HIV infections. WG3 promotes this scientific agenda through a variety of activities including (1) facilitating collaborative research by sponsoring seminars, journal clubs, research-in-progress meetings, and targeted meetings to discuss HIV initiatives, (2) forming and participating in national research consortia to promote and disseminate HIV research, and (3) mentoring and promoting the careers of junior investigators. Through these activities, WG3 will promote the following Specific Aims: • To develop new interactions among investigators from various disciplines. Key scientific priorities are: • To stimulate the formation of multi-investigator projects. WG2 success will be defined by the advancement of new collaborative projects, including: • To stimulate cross-fertilization between working groups. In summary, WG3 is focused on promoting key scientific priorities for HIV research in the ART era. This agenda will be supported through targeted activities designed to foster collaborations within the CWRU/UH CFAR, develop supporting resources in the CFAR Cores, especially the Clinical Core D and Uganda Laboratory Core C. The WG3 has placed emphasis on engaging new investigators and has an excellent record of supporting the work of Mentored Scientist Pilot Grant and Catalytic Fund awardees.